AAVantgarde and TIGEM Publish Groundbreaking Research in Science AdvancesMILAN, March 31, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company, in collaboration with the Telethon Institute of Genetics and Medicine (TIGEM), announces the publication of their preclinical research in Stargardt’s disease in Science Advances, a prestigious peer-reviewed journal. This breakthrough study underscores the companies' joint commitment to advancing gene therapy and expanding the frontiers of scientific discovery.
AAVantgarde announces 2 presentations at ARVO 2025 annual meeting: LUCE-1 clinical trial data from Usher 1B program & NHP GLP data from Stargardt disease programMILAN, March 10, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company, today announces the publication of two abstracts submitted to The Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), to be held May 4-8, 2025 in Salt Lake City (US).
AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B at FLORetina 2024MILAN, Dec. 09, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), an Italy-based global biotechnology company, presented preliminary safety data on the first two subjects dosed in the LUCE-1 trial, a Phase 1/2 open label clinical trial to assess safety and tolerability of AAVB-081, using the company’s proprietary dual hybrid gene therapy platform to deliver MYO7A protein in subjects with retinitis pigmentosa related to Usher Syndrome Type 1B (USH1B).
AAVantgarde announces oral presentation of LUCE-1 clinical study at FLORetina 2024 annual meetingMILAN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces an oral presentation at the FLORetina Annual Meeting, to be held December 5-8 in Florence (Italy). At this conference, safety results at 60 days for the two first subjects with advanced retinitis pigmentosa due to Usher syndrome 1B dosed in the LUCE-1 study will be presented by Prof. Francesca Simonelli, Principal Investigator for this study. This is the first administration of a dual AAV gene therapy in Ophthalmology.
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis PigmentosaMILAN, Dec. 02, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead program, AAVB-081 for the treatment of Usher Syndrome Type 1B (USH1B) retinitis pigmentosa.
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell TherapyMILAN, Oct. 28, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, is pleased to congratulate Professor Alberto Auricchio, the Company’s Founder and Chief Scientific Officer (CSO), on his appointment as President and Board member of the European Society of Gene and Cell Therapy (ESGCT). The ESGCT Board is composed of researchers and clinicians representing a broad range of European Countries. Members are elected by nomination and vote at the Annual General Meeting. Election to the Board of ESGCT is a great honor and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business OfficerMILAN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the appointment of Lauren Kaskiel, MBA, as their Chief Business Officer. Ms. Kaskiel brings more than 20 years of experience in the biotech and pharmaceutical industry and has joined the Company’s leadership team, reporting to Dr. Natalia Misciattelli, Chief Executive Officer.
AAVantgarde announces 3 oral presentations at ESGCT 2024 annual meetingMILAN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces three oral presentations at the European Society of Gene & Cell Therapy 31st Annual Meeting (ESGCT), to be held October 22-25 in Rome. AAVantgarde is validating its platform technology in two inherited retinal diseases with clear unmet need, with Usher syndrome type 1B already in the clinic and Stargardt advancing towards clinical development.
AAVantgarde announces first patient dosed in First-In-Human Phase 1/2 LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1BMILAN, Italy, Sept. 16, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), an Italy-based global biotechnology company, announced that the first subject has been dosed in the LUCE-1 trial, a Phase 1/2 open label clinical trial to assess safety and tolerability of AAVB-081, using the company’s proprietary dual hybrid gene therapy platform to deliver MYO7A protein in subjects with retinitis pigmentosa related to Usher Syndrome Type 1B (USH1B).
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical OfficerMILAN, Italy, Sept. 09, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the appointment of Jayashree Sahni, MD, FRCOphth, EMBA as their Chief Medical Officer. Dr. Sahni brings more than 25 years of ophthalmology and drug development experience to AAVantgarde and has joined the Company’s leadership team, reporting to Dr. Natalia Misciattelli, Chief Executive Officer.
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1BMILAN, Italy, May 03, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the presentation of the clinical trial design of the Company’s lead program in Usher 1B by the program’s Principal Investigator, Prof. Francesca Simonelli, at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit, being held today in Seattle.
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meetingMILAN, Italy, April 24, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the publication of an abstract submitted to The Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), to be held May 5-9 in Seattle.
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meetingMILAN, Italy, April 23, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announces the publication of an abstract accepted as an oral presentation submitted to The American Society of Gene & Cell Therapy 27th Annual Meeting (ASGCT), to be held May 7-11 in Baltimore.
